Announcement PDF ASX ANNOUNCEMENT 5 May 2025 Investor Webinar Melbourne, Australia; 5 May 2025: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, reminds shareholders that CEO and Managing Director, Dr Kilian Kelly, will host an investor webinar today, Monday 5 May 2025 at 10:30am AEST. Attendees are required to register in advance for the webinar – using the following link: https://us02web.zoom.us/webinar/register/WN_AvnG-LrtTYOzU3TvHGdn3A Upon registration, attendees will receive a link to access the webinar. A copy of the presentation to be delivered during the webinar is attached to this announcement. -ENDSAuthorised for release by Dr Kilian Kelly, CEO & Managing Director CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Lauren Nowak, Media Contact, +61 (0)400 434 299, lauren@littlebigdeal.au About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK, in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD), and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com A Clinical Stage Company Pioneering the Next Generation of Cellular Therapies Investor Webinar 5 May 2025 Important information Summary information Forward-looking statements This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (CYP, or Cynata) which is current as at 2 May 2025. This Presentation should be read in conjunction with CYP’s other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au. This Presentation contains certain ‘forward looking statements’, which can generally be identified by the use of forward looking words such as ‘expect’, ‘anticipate’, ‘likely’, ‘intend’, ‘should’, ‘could’, ‘may’, ‘predict’, ‘plan’, ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’ and other similar expressions. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of CYP, its directors and management, and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements. Not an offer This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws. Not investment advice This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been prepared without taking account of any person’s individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities. Investment risk and past performance An investment in CYP securities is subject to known and unknown risks, some of which are beyond the control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP performance including future share price performance. Financial data All financial information in this Presentation is in Australian currency (A$) unless otherwise stated. This Presentation contains historical financial information based on financial information that has been disclosed to the ASX. Any discrepancies between totals and sums of components in tables and figures in this Presentation are due to rounding. Industry and Market data Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither CYP nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications. Disclaimer To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (Related Persons) exclude and disclaim all liability, including without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice. 2 Corporate overview Cynata Therapeutics Limited (ASX:CYP) Largest shareholders • Clinical stage biotechnology company, headquartered in Melbourne, Australia • Commercialising the novel Cymerus • Scalable and consistent production of potent cell-based therapies for a range of serious medical disorders iPSC1-based platform 3.6% Share price performance Share price (2 May 2025) A$0.195 Shares on issue ~225m Market capitalisation ~A$44m Cash2 ~ A$8.5m 2 As at 31 March 2025 10.0% Top 20 shareholders hold ~47% of shares on issue Financial information 1 iPSC = induced Pluripotent Stem Cell 10.3% 3 Clinical pipeline INDICATION PHASE 1 PHASE 2 PHASE 3 Osteoarthritis (OA) (managed by USYD, funded by NHMRC) Acute Graft vs Host Disease (aGvHD) FDA Orphan Designation Diabetic Foot Ulcers (DFU) Kidney Transplantation (managed and funded by LUMC) Note: Cynata retains commercial rights for both of the partner funded & managed programs 4 March 2025 Quarter – Key Highlights Phase 2 clinical trial in aGvHD • Trial ongoing at >35 clinical centres in Australia, USA, EU and Turkey • Patient enrolment has progressed very well in recent months; now >60% complete • Completion of enrolment anticipated ~Jul 2025 • Primary results (after 100 days’ follow-up) still anticipated late 2025 Phase 3 clinical trial in osteoarthritis • • • • Patient enrolment completed in Nov 2023 Patient treatment completed in Nov 2024 Last patient visit expected in Nov 2025 Results expected H1 2026 Phase 1 clinical trial in kidney transplantation • First patient received CYP-001 in Dec 2024 • Patient enrolment continues; Cohort 1 completion expected during the currently ongoing quarter Further scientific validation • Paper underlining strengths of Cymerus platform published in npj Regenerative Medicine, a leading peer-reviewed journal published by Nature Portfolio • Key findings: • Effects of MSCs largely driven by secretomes (proteins and other molecules released by cells) • Cymerus MSC secretomes contained many more unique proteins and showed greater immunomodulatory effects than secretomes of donor-tissue derived MSCs • Secretomes of iPSC-derived and umbilical cord-derived MSCs resulted in significantly faster wound closure than bone marrow or adipose tissue-derived MSCs Reminder – DFU Phase 1 trial results Diabetes fastest growing disease worldwide1 Est. 38 million Americans have diabetes2 Up to 34% of those with diabetes will develop a foot ulcer3 150,000+ lower extremity amputations per year in the US following chronic DFU4 12w 1. 2. 3. 24w Hossain et al. Health Sci Rep. 7(3):e2004 (2024). American Diabetes Association: https://diabetes.org/about-diabetes/statistics/about-diabetes McDermott et al. Diabetes Care. 46:209–221 (2023). Estimated annual costs to US public and private payers: US$9– 13 billion5 Larger wounds measuring >200 mm² These results are highly encouraging when compared with the results achieved using current standard of care (SOC) Reduction in wound size (i.e. improvement) Mean change in wound surface area (all wounds) More than 15% of foot ulcers result in amputation of the foot or limb3 12w 24w 4. American Diabetes Association: https://diabetes.org/advocacy/amputation-prevention-alliance 5. Raghav et al. Ther Adv Endocrinol Metab. 9(1) 29-31 (2018). For further information on the Phase 1 clinical trial: https://clinicaltrials.gov/study/NCT05165628 10 Outlook and commercial potential Industry connections • We are continuing to progress partnering discussions with various partners, regarding various assets • Upcoming catalysts will accelerate and broaden partnering discussions • We continue to attend leading conferences in our sector, to tell our story and open new discussion JP Morgan BioWeek/Biotech Showcase Company presentation, partnering meetings Advanced Therapies Congress Company presentation, partnering meetings International Society of Cell and Gene Therapy Invited speaker, partnering meetings International Society of Stem Cell Research Invited speaker BIO International Partnering meetings San Francisco, January 2025 London, March 2025 New Orleans, May 2025 Hong Kong, June 2025 Boston, June 2025 12 Upcoming catalysts* DFU results announced Dec 2024; results from three further trials expected by 1H 2026 PHASE 1 DFU Results announced – Dec 2024 PHASE 2 aGvHD Enrolment complete Results Phase 3 osteoarthritis Results Phase 1/2 kidney transplantation Results (Cohort 1) Q1 2025 Q2 2025 Q3 2025 * Timing of events is approximate, based on the Company’s information as at the date of this presentation, and subject to change Q4 2025 Q1 2026 Q2 2026 13 Cynata Therapeutics Ltd Level 3, 100 Cubitt Street Cremorne, Victoria 3121, Australia info@cynata.com www.cynata.com